Under a tenth of people that would benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it releases its initial advice on the therapies.
With more than one billion individuals worldwide currently obese, it is calling for increased and just access to this class of drugs.
According to estimates, more than two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidelines affirms that excess weight is a lifelong illness that can be treated with comprehensive and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to widespread availability to the injections that can aid individuals in losing significant weight, says the organization.
Skinny Jab Shortage
Despite the present best projected outlook, the supply of such drugs would only suffice for about 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation encourages nations and manufacturers to widen access, by approaches such as licensing agreements.
A patent on the active ingredient – the primary ingredient of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Drugs Operate
These medications imitate a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so people eat less.
Individuals typically see weight reduction after several weeks of commencing the weekly injections.
Evidence points to patients may regain a significant portion within a year of discontinuing the treatment, when their normal hunger resume.
Being carrying excess weight elevates your risk for developing medical conditions, such as diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight impacts individuals in countries worldwide and was linked to millions of deaths worldwide in 2024, as per the WHO.
